Cytokines as mediators of the associations of prenatal exposure to phenols, parabens, and phthalates with internalizing behaviours at age 3 in boys: a mixture exposure and mediation approach

Olfa Khalfallah; Susana Barbosa; Claire Phillipat; Remy Slama; Cédric Galera; Barbara Heude; Nicolas Glaichenhaus; Laetitia Davidovic

doi:10.1101/2023.03.13.23287180

ABSTRACT

Childhood internalizing disorders refer to inwardly focused negative behaviours such as anxiety, depression, and somatic complains. Interactions between psychosocial, genetic, and environmental risk factors adversely impact neurodevelopment and can contribute to internalizing disorders. While prenatal exposure to single endocrine disruptors (ED) is associated with internalizing behaviours in infants, the associations with prenatal exposure to ED in mixture remain poorly addressed. In addition, the biological mediators of ED mixture effects on internalizing behaviours remain unexplored. ED do not only interfere with endocrine function, but also with immune function and inflammatory processes. Based on this body of evidence, we hypothetised that inflammation at birth is a plausible biological pathway through which ED prenatal exposure could operate to influence offspring internalizing behaviours. Based on the EDEN birth cohort, we investigated whether ED mixture exposure increased the odds of internalizing disorders in 459 boy infants at age 3, and whether the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α measured at birth are mediators of this effect. To determine both the joint and individual associations of ED prenatal exposure with infant internalizing behaviours and the possible mediating role of cytokines, we used the counterfactual hierarchical Bayesian Kernel Machine Regression (BKMR) regression-causal mediation analysis. We show that prenatal exposure to a complex ED mixture has limited effects on internalizing behaviours in boys at age 3. We also show that IL-1β, IL-6, and TNF-α are unlikely mediators or suppressors of ED mixture effects on internalizing behaviours. Further studies on larger cohorts are warranted to refine the deleterious effects of ED mixtures on internalizing behaviours and identify possible mediating pathways.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

NG and RS are grateful to the Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail ANSES (Environnement-santé-travail funding scheme) for funding the present research. LD, CG, and BH thank the the Fondation de France (Autism and neurodevelopment funding scheme) for funding the present research. The funders played no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; or the decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The EDEN cohort promoted by INSERM has received approval from the CCPPRB (Comité consultatif de protection des personnes dans la recherche biomédicale, the French Institutional Ethic Board for human subjects biomedical research) of Kremlin Bicêtre and from the CNIL (Commission Nationale Informatique et Liberté, the French national agency on data privacy) for biological samplings and data collection. The use of EDEN samples and data in the present study has been approved by the EDEN steering committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes